20/20 BIOLABS, INC. Stock-Based Compensation
20/20 BIOLABS, INC. (AIDX) reported Stock-Based Compensation of $499.74 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- 20/20 BIOLABS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $371.30K, a 186.39% increase year-over-year.
- 20/20 BIOLABS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $128.44K, a 0.93% decline year-over-year.
- 20/20 BIOLABS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was $129.65K.
- 20/20 BIOLABS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-03-31 was $129.65K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $371.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $499.74K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $128.44K 10-Q · filed 2026-05-20 | ||
| 2025-12-31 | $516.18K POS AM · filed 2026-04-06 | ||
| 2025-06-30 | $129.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $259.30K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $129.65K 10-Q · filed 2026-05-20 | ||
| 2024-12-31 | $2.18M POS AM · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |